These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 27503452)

  • 41. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
    Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J
    Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346
    [No Abstract]   [Full Text] [Related]  

  • 42. Use of psychedelics in the Czech Republic: results of recent population surveys.
    Chomynová P; Kočárová R; Kňažek F; Plevková M; Bláhová B; Valeš K; Mravčík V
    Cent Eur J Public Health; 2022 Sep; 30(3):144-153. PubMed ID: 36239361
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trends in the Top-Cited Articles on Classic Psychedelics.
    Lawrence DW; Sharma B; Griffiths RR; Carhart-Harris R
    J Psychoactive Drugs; 2021; 53(4):283-298. PubMed ID: 33535907
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.
    Goldberg SB; Shechet B; Nicholas CR; Ng CW; Deole G; Chen Z; Raison CL
    Psychol Med; 2020 Dec; 50(16):2655-2666. PubMed ID: 33143790
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D; Weissman C; Anderson T; Petranker R; Dinh-Williams LA; Hui K; Hapke E
    J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An introduction to psychedelic neuroscience.
    Calvey T; Howells FM
    Prog Brain Res; 2018; 242():1-23. PubMed ID: 30471677
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Psychedelics in the treatment of substance use disorders and psychosis].
    van den Brink W; Breeksema JJ; Vermetten E; Schoevers RA
    Tijdschr Psychiatr; 2020; 62(8):650-658. PubMed ID: 32816293
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Compassionate use of psychedelics.
    Greif A; Šurkala M
    Med Health Care Philos; 2020 Sep; 23(3):485-496. PubMed ID: 32468195
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Classic hallucinogens in the treatment of addictions.
    Bogenschutz MP; Johnson MW
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():250-8. PubMed ID: 25784600
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Culture, context, and ethics in the therapeutic use of hallucinogens: Psychedelics as active super-placebos?
    Dupuis D; Veissière S
    Transcult Psychiatry; 2022 Oct; 59(5):571-578. PubMed ID: 36263513
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions.
    Garcia-Romeu A; Richards WA
    Int Rev Psychiatry; 2018 Aug; 30(4):291-316. PubMed ID: 30422079
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics.
    Moreton SG; Szalla L; Menzies RE; Arena AF
    Psychopharmacology (Berl); 2020 Jan; 237(1):21-32. PubMed ID: 31784805
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Psychedelics.
    Nichols DE
    Pharmacol Rev; 2016 Apr; 68(2):264-355. PubMed ID: 26841800
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action.
    Rieser NM; Herdener M; Preller KH
    Curr Top Behav Neurosci; 2022; 56():187-211. PubMed ID: 34910289
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review.
    DiVito AJ; Leger RF
    Mol Biol Rep; 2020 Dec; 47(12):9791-9799. PubMed ID: 33231817
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Classic psychedelic drugs and their potential therapeutic effect].
    Bayat M
    Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918777
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports.
    Nayak SM; Gukasyan N; Barrett FS; Erowid E; Erowid F; Griffiths RR
    Pharmacopsychiatry; 2021 Sep; 54(5):240-245. PubMed ID: 34348413
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Psychedelic medicines for mood disorders: current evidence and clinical considerations.
    Sarris J; Pinzon Rubiano D; Day K; Galvão-Coelho NL; Perkins D
    Curr Opin Psychiatry; 2022 Jan; 35(1):22-29. PubMed ID: 34855694
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Advances and challenges in neuroimaging studies on the effects of serotonergic hallucinogens: Contributions of the resting brain.
    Müller F; Liechti ME; Lang UE; Borgwardt S
    Prog Brain Res; 2018; 242():159-177. PubMed ID: 30471679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.